Mann Henry J, Short Mary A, Schlichting Douglas E
College of Pharmacy, Center for Excellence in Critical Care, University of Minnesota, Minneapolis, MN 55455, USA.
Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. doi: 10.2146/ajhp080276.
The role of protein C in critical illness is assessed.
Conversion of protein C to activated protein C (APC) requires thrombin and thrombomodulin. When thrombin is not bound to thrombomodulin, it can convert fibrinogen to fibrin, factor V to factor Va, and factor VIII to factor VIIIa but will not convert protein C to APC. When thrombin is bound to thrombomodulin, it can convert protein C to APC but cannot convert fibrinogen, factor V, or factor VIII. Activation of protein C is accelerated by the presence of endothelial protein C receptors. In conjunction with protein S, APC limits coagulation by inactivating factors Va and VIIIa, which decreases thrombin-mediated inflammation. By inhibiting the formation of thrombin and the release of proinflammatory cytokines, APC reduces the inflammatory response to infection. By inducing cell signaling, APC directly modulates the cellular response to infection, resulting in antiinflammatory, cytoprotective, and barrier-protective activities. APC is metabolized by protease inhibitors and other proteins in the plasma. Conversion of protein C to APC is impaired in severe sepsis. During severe sepsis, endogenous levels of the inactive precursor protein C are reduced because of decreased production by the liver and degradation by enzymes. More than 85% of patients with severe sepsis have low levels of protein C. Absolute levels of protein C correlate with morbidity and mortality outcomes of the sepsis population, regardless of age, infecting microorganism, presence of shock, disseminated intravascular coagulation, degree of hypercoagulation, or severity of illness.
The protein C pathway is a natural homeostatic regulator with multiple mechanisms of action. Blood protein C concentration is inversely correlated with morbidity and mortality in sepsis and other critical illness.
评估蛋白C在危重病中的作用。
蛋白C转化为活化蛋白C(APC)需要凝血酶和血栓调节蛋白。当凝血酶未与血栓调节蛋白结合时,它可将纤维蛋白原转化为纤维蛋白、因子V转化为因子Va、因子VIII转化为因子VIIIa,但不会将蛋白C转化为APC。当凝血酶与血栓调节蛋白结合时,它可将蛋白C转化为APC,但不能转化纤维蛋白原、因子V或因子VIII。内皮蛋白C受体的存在可加速蛋白C的活化。与蛋白S一起,APC通过灭活因子Va和VIIIa来限制凝血,从而减少凝血酶介导的炎症。通过抑制凝血酶的形成和促炎细胞因子的释放,APC可减轻对感染的炎症反应。通过诱导细胞信号传导,APC直接调节细胞对感染的反应,从而产生抗炎、细胞保护和屏障保护作用。APC在血浆中被蛋白酶抑制剂和其他蛋白质代谢。在严重脓毒症中,蛋白C向APC的转化受损。在严重脓毒症期间,由于肝脏产生减少和酶降解,无活性前体蛋白C的内源性水平降低。超过85%的严重脓毒症患者蛋白C水平较低。无论年龄、感染微生物、休克的存在、弥散性血管内凝血、高凝程度或疾病严重程度如何,蛋白C的绝对水平与脓毒症患者的发病率和死亡率结果相关。
蛋白C途径是一种具有多种作用机制的天然稳态调节因子。血液中蛋白C浓度与脓毒症和其他危重病的发病率和死亡率呈负相关。